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August 16, 2005:730–42he primary outcome measure, was initiated. Of the 59 patients, 29
ere assigned randomly to 1 mg of oral vitamin K and 30 were
ssigned to withhold warfarin only. Baseline characteristics are
ummarized in Table 1, and results are summarized in Table 2. No
ajor bleeding events occurred in either group. There was one
pisode of minor bleeding (epistaxis) in the vitamin K group and
o episodes in the control group. One patient died in the vitamin
group because of acute pulmonary edema; no deaths were
ecorded in the control group.
This randomized clinical trial is the first to examine the efficacy
f oral vitamin K in patients with mechanical heart valves.
ompared with “no treatment,” 1 mg of oral vitamin K more
ommonly returned prolonged INR values to the therapeutic or
ear-therapeutic range within one day. Given that major bleeding
an occur in as many as 4% of patients who present with an INR
6.0 who are treated with simple warfarin withdrawal (1), this
nding may be clinically relevant. In our study, only 3.4% of
atients treated with low-dose oral vitamin K had INR values
5.0 at 24 h after administration of the study drug. In contrast,
3.3% of the patients who simply withheld warfarin had INR
alues 5.0 at 24 h after study enrollment (p  0.001).
The administration of vitamin K produced what we defined as
n over-reversal in approximately 10% of patients. The difference
etween the two groups in the proportion of patients with INR
alues 1.8 was not statistically significant, and none of the
atients in this study had thrombotic events during follow-up.
evertheless, such a high proportion of patients with an INR less
han the therapeutic range raises the concern that low-dose oral
itamin K may increase the risk of thromboembolism in this
opulation; we anticipate that the results of our ongoing multina-
ional study will determine whether oral vitamin K, administered
n this setting, is associated with thromboembolism.
Our study had two important limitations. First, we used the
NR, rather than clinical outcomes, as the primary outcome
easure. Although the INR is a validated surrogate marker for
leeding and thrombotic complications in stably anticoagulated
able 2. Study Results
Vitamin K No Treatment p Value
umber 29 30
ean INR day 0 7.22 7.72
ean INR day 1 2.99 5.23
umber of patients with
INR 2.3–4.5 on day 1
13 4 0.001*
umber of patients with
INR 1.8 on day 1
3 0 NS
Odds ratio 5.3, 95% confidence interval 1.3 to 25.5.
Abbreviations as in Table 1.atients, its association with these complications is less clear when
Results From the International Reg
oncomitant CHF has remained largely restricted to case reports
(
u
C
the INR is changing rapidly (for example, during warfarin initia-
ion or after administration of oral vitamin K). Second, this study
as terminated prematurely, and the enrollment target was not
eached. Nonetheless, the observed difference in the primary end
oint was statistically significant. Even if target enrollment had
een reached, it is unlikely that our findings would have had
ufficient power either to detect differences in clinical outcomes or
o demonstrate a statistically rigorous association between oral
itamin K administration and an INR 1.8 on day 1.
In summary, our study provides additional support for the
ypothesis that the administration of 1 mg of oral vitamin K is very
ffective for the treatment of asymptomatic warfarin-associated
oagulopathy in patients presenting with INR values 6.0. Our
nthusiasm for this treatment is, however, tempered by the
bservation that about one in 10 patients who receive vitamin K
ill have an INR of 1.8 on the day following vitamin K
dministration; it is possible that these patients are at risk for
voidable thrombosis.
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atteo Galli, MD
ark Crowther, PhD
U.O. Medicina Interna
spedale di Circolo
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-mail: agewal@yahoo.com
doi:10.1016/j.jacc.2005.05.022
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warfarin. Thromb Haemost 1998;79:1116–8.Acute Aortic Dissection Presenting With Congestive Heart Failure:
istry of Acute Aortic Dissectiono the Editor: Congestive heart failure (CHF) has long been
ecognized as a potential complication of aortic dissection (AoD);
owever, the understanding of the presentation of AoD with1–6). Therefore, we undertook the present analysis to better
nderstand the characteristics and outcomes of patients with acute
HF at the time of AoD, as well as the impact of CHF on the
ime to AoD recognition and treatment.
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734 Correspondence JACC Vol. 46, No. 4, 2005
August 16, 2005:730–42The design and initial results from the International Registry of
ortic Dissection (IRAD) have been previously described in detail
7). At the time of our study, 1,069 subjects were eligible for
nalysis. Of these, 64 subjects (6%) presented with acute CHF at
he time of their AoD. The diagnosis of CHF was made based on
he impressions of the managing physicians as noted in the IRAD
ase report form.
The characteristics of CHF patients compared with those
ithout acute CHF at presentation are detailed in Table 1.
atients with CHF at presentation were less likely than those
ithout to have chest pain. Moreover, when pain was present in a
atient with CHF, the pain was more often mild and less likely
brupt in onset. Patients with CHF and AoD were less likely to be
ypertensive on presentation but more likely to present in shock
ompared with those without CHF. On examination, the murmur
f aortic regurgitation was present more often in patients with
HF. Patients presenting with CHF at the time of dissection were
ore likely to have Stanford type A AoD than were those without.
dditionally, aortic dimensions often were larger among patients
ith CHF (Table 1).
The median times from symptom onset to presentation, diag-
osis, or surgical intervention were all consistently longer among
atients with CHF (Fig. 1). In multivariate analyses, CHF was not
ssociated with delays in presentation (odds ratio [OR] 1.27, 95%
onfidence interval [CI] 0.63 to 2.57, p  0.50); a trend toward
elay in diagnosis was noted among patients with CHF (OR 1.72,
Table 1. Baseline Characteristics of Aortic Dis
Characteristic
Age, yrs (mean  SD)
Male gender
Hypertension
Atherosclerosis
Known aortic valve disease
Bicuspid aortic valve
Known aortic aneurysm
Prior coronary artery bypass graft
Symptoms
Chest pain
Pain severity (if present)
Mild
Severe
Abrupt onset of pain (if present)
Signs
Hypotension (SBP 100 mm Hg)
Hypertension (SBP 150 mm Hg)
Shock (SBP 80 mmHg)
Murmur of aortic regurgitation
Pulse deficits
Type of dissection
Type A
Type B
Aortic measurements (cm, mean  SD)
Aortic annulus
Aortic root
Sinotubular junction
Ascending aorta
Aortic arch
Descending aorta
CHF  congestive heart failure; SBP  systolic blood pres5% CI 0.87 to 3.39, p  0.11). Importantly, CHF was an
a
bndependent predictor of a delay in surgical intervention (OR 4.53,
5% CI 1.62 to 12.6, p  0.004).
Mortality rates were similar among type B AoD patients with
HF and without CHF (23% vs. 12%, p  0.22); the mortality
ates were identical (30%) among those who had type A AoD.
verall mortality was 13% for type B AoD and 29.4% for type A
issection.
In this analysis, we have identified key differences between the
on Patients With and Without CHF
F
64)
No CHF
(n  1,005) p Value
17 62  14 0.58
% 69% 0.04
% 72% 0.23
% 30% 0.02
% 8% 0.01
% 3% 0.05
% 14% 0.05
% 5% 0.004
% 78% 0.002
% 7% 0.001
% 72% 0.01
% 88% 0.001
% 11% 0.70
% 47% 0.02
% 9% 0.01
% 32% 0.008
% 27% 0.55
0.003
% 61%
% 39%
1.3 3.1  0.87 0.23
1.7 4.2  1.0 0.11
1.9 3.9  1.0 0.27
2.0 4.8  1.3 0.02
1.4 3.8  0.96 0.20
2.3 4.1  1.2 0.09
igure 1. Median times from symptom onset to presentation, diagnosis ofsecti
CH
(n 
63 
56
65
44
19
12
23
15
60
29
55
70
13
32
19
49
31
80
20
3.4 
4.8 
4.7 
5.6 
4.2 
4.8 ortic dissection, and surgery, expressed as a function of the presence (solid
ars) or absence (cross-hatched bars) of congestive heart failure (CHF).
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735JACC Vol. 46, No. 4, 2005 Correspondence
August 16, 2005:730–42linical characteristics and testing results in those with and without
HF at the time of their AoD. Those with CHF tended to
resent in atypical fashion, and whereas CHF at the time of AoD
id not appear to lead to inordinate delays in patient presentation,
potential impact of CHF on time to recognition of AoD was
oted, and CHF was an independent predictor of surgical delay. In
ur data set, it is unclear whether these delays were due to clinician
reoccupation with CHF or the more subtle presentation of those
ith CHF and AoD.
Previous case reports have suggested that CHF in the presence
f AoD is due to aortic regurgitation from aortic valve disease,
ncomplete aortic leaflet closure (due to dilation of the sinotubular
unction), or aortic valve disruption (1,2,5). An additional mech-
nism of CHF at the time of AoD includes high-output heart
ailure (3,4,6). Although we confirm a high percentage of patients
ith CHF secondary to proximal aortic involvement, we also
emonstrated that as many as 20% of patients with CHF at the
ime of AoD had a distal dissection; consequently, in this consid-
rable minority, the mechanism of CHF must be something other
han direct aortic valve involvement by the dissection itself, such as
yocardial ischemia/infarction or hypertension. Delays in AoD
iagnosis and treatment are notable in our subjects; this may reflect
onsideration of diagnoses alternative to AoD, given the atypical
resentation in our subjects.
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disease. JAMA 2000;283:897–903.Heritability of Left Ventricular Mass and Other Morphologic Variables
orthern Manhattan Family Studyo the Editor: Left ventricular (LV) hypertrophy is a risk factor
or cardiovascular disease (1–3) and ischemic stroke (4–6). Cur-
ent data suggest that genetic factors and traditional cardiovascular
isk factors contribute to left ventricular mass (LVM) and LV
ypertrophy. Several studies demonstrated substantial genetic
ontribution to LVM in white, black, and American Indian
opulations (7–12). However, no data exist on heritability of LVM
n Hispanic patients.
Echocardiographically derived LVM has been validated by
omparison with autopsy data (13). From LVM and relative wall
hickness (RWT), three abnormal geometric patterns (i.e., con-
entric hypertrophy, eccentric hypertrophy, and concentric remod-
ling) (14) can be derived, and they appear to carry different risks
or cardiovascular events (6).
In the current study, we tested for the significance of heritability
or several LVM-related phenotypes in the high-risk Caribbean
ispanic families from the ongoing Northern Manhattan Family
tudy (NOMAFS). The detailed ascertainment scheme has been
escribed elsewhere (15). Transthoracic echocardiography was
erformed according to the guidelines of the American Society ofLVDD), left ventricular end-systolic diameter (LVSD), interven-
ricular septum (IVS), and posterior wall thickness (PWT) at end
iastole were measured. To minimize variability, we took mea-
urements in triplicate and averaged them.
Left ventricular mass was calculated from the corrected Amer-
can Society of Echocardiography method (13): LVM  0.8 (1.04
(LVDD  IVS  PWT)3  LVDD3])  0.6. Heritability of
VM also was assessed after correction for the indices of body size
ost commonly used in published reports: body surface area
LVM/BSA), height (LVM/HT), and height to the 2.7 power
LVM/HT2.7). The heritability of LVDD, LVSD, IVS, PWT,
nd RWT also was assessed. Relative wall thickness was calculated
ccording to two formulas: (IVS  PWT)/LVDD and 2 · PWT/
VDD (14). Echocardiographic studies were interpreted by re-
earchers who were blinded to the clinical characteristics. Interob-
erver variability ranged between 8% and 10%.
All the quantitative phenotypes were expressed as the mean and
tandard deviation. Log transformations were used for non-
ormally distributed variables. We used the Sequential Oligogenic
inkage Analysis Routines (SOLAR) package (Southwest Foun-
ation for Biomedical Research, San Antonio, Texas) (17) to
